Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176565 | 0.91 | LIPG (0.40) | LPLLIPGIMPDH2DGAT1PDGFRB | |
| SCHEMBL20176633 | 0.91 | LIPG (0.40) | LPLLIPGIMPDH2DGAT1PDGFRB | |
| SCHEMBL20176628 | 0.91 | LIPG (0.47) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL20176444 | 0.89 | LIPG (0.50) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL14478695 | 0.84 | LPL (0.41) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL20176454 | 0.84 | LPL (0.38) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL20176693 | 0.84 | LIPG (0.44) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL20176833 | 0.84 | LIPG (0.44) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL20176461 | 0.83 | ENPP1 (0.40) | LPLLIPGDGAT1PDGFRBKDR | |
| SCHEMBL20176788 | 0.83 | LPL (0.56) | LPLLIPGDGAT1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2023-06-06 | — | — | US | disclosed |
| WO-2018093231-A1 | ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING SAME | 주식회사 두산 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667622-B2 | Organic light emitting compound and organic electroluminescence device using same | OR10J3, ICMT, SLCO4C1 | LPL 695/4885LIPG 812/4885IMPDH2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.